Earnings reports show mixed performances for Lynas Rare Earths, NOV Inc., Clean Harbors, and Labcorp Holdings, with challenges, adjustments, and cautious outlooks amid market volatility.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.
Earnings reports show mixed performances for Lynas Rare Earths, NOV Inc., Clean Harbors, and Labcorp Holdings, with challenges, adjustments, and cautious outlooks amid market volatility.
Pfizer sues Novo Nordisk to block its $8.5-$9B bid for Metsera, alleging antitrust violations and a 'kill' strategy to preserve dominance in GLP-1 obesity drugs.